Search for: "Schering Corporation" Results 41 - 60 of 136
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
9 Sep 2011, 8:40 am by Peter Rost
He also provides consulting services on corporate therapeutics and ethics guidelines. [read post]
27 Aug 2011, 7:55 pm
Bayer Schering., 575 F.3d at 1347. [read post]
3 Aug 2011, 5:11 am by Lawrence B. Ebert
In the Pipeline suggests Merck's discovery research might move out of Rahway and to the former Schering-Plough site in Kenilworth. [read post]
22 Jun 2011, 7:09 am by Peter Rost
He also provides consulting services on corporate therapeutics and ethics guidelines. [read post]
30 May 2011, 4:55 am by Marie Louise
Egg World, LLC (Seattle Trademark Lawyer) Parties choose ACR, TTAB finds SOLARIN not confusingly similar to SOLARCAINE for sun/tanning products: Schering-Plough HealthCare Products, Inc. v. [read post]
23 May 2011, 1:54 pm by FDABlog HPM
(“Merck”) (formerly Schering-Plough Corporation) restricted competition in violation of the Sherman Act by settling patent infringement lawsuits against potential generic K-DUR entrants. [read post]
22 Apr 2011, 10:51 am by Zoe Tillman
Merck merged with Schering-Plough Corp. on Nov. 3, 2009, and, according to the complaint, had told PETA that they needed to prove ownership in Schering-Plough to be eligible. [read post]
25 Mar 2011, 4:29 pm by Eric Schweibenz
., Inc. of Whitehouse Station, New Jersey Schering Plough Corporation of Kenilworth, New Jersey Organon USA, Inc. of Durham, North Carolina N.V. [read post]
28 Feb 2011, 6:58 pm by Eric Schweibenz
Organon, which is a wholly owned subsidiary of Merck & Co., Inc. and is related to Organon USA, Inc. and Schering Plough Corporation. [read post]
11 Feb 2011, 7:51 am by Peter Rost
Peter Rost is a former Pfizer Marketing Vice President providing services as an expert witness on pharmaceutical marketing and consulting services on corporate therapeutics and ethics guidelines. [read post]
10 Jan 2011, 11:00 am
Cain (the “Shareholders”), holders of eleven shares of defendant Schering-Plough Corporation (the “Company”), filed a shareholder derivative complaint against defendant Company for corporate mismanagement and wrongdoing in connection with the failure to make a timely disclosure of the results of a drug trial for one of Schering’s products called ENHANCE. [read post]
9 Nov 2010, 3:09 pm
Cancer Research Technology & Schering v. [read post]
6 Oct 2010, 12:54 am by Matthew Hill
The BBC had made submissions on this point, based on the case of Schering Chemicals Ltd v Falkman Ltd [1982] 1 QB 1. [read post]
2 Oct 2010, 8:43 am by Peter Rost
Peter Rost is a former Pfizer Marketing Vice President providing services as an expert witness on pharmaceutical marketing and consulting services on corporate therapeutics and ethics guidelines. [read post]
15 Sep 2010, 2:40 am by Kelly
KG v Apotex Pty Ltd (No 2) (Patentology) MoviPrep – US: Salix and Norgine settle with Novel in patent dispute over MoviPrep (Patent Docs) Nexavar (Sorafenib) – India: Nexavar patent infringement suit before Delhi HC goes directly to trial: Bayer v Cipla (Spicy IP) Simcor (Niacin/Simvastatin) – US: Abbott files patent infringement suit against Teva following Para IV challenge (Patent Docs) Vancocin (Vancomycin) – US: ViroPharma sues FDA over generic Vancocin; alleges that FDA… [read post]
21 Aug 2010, 10:22 am by Lawrence B. Ebert
Impax filed an ANDA on VYTORIN(R) (ezetimibe/simvastatin), and Schering Corporation and MSP Singapore Co. [read post]
20 Aug 2010, 12:56 pm by Stephen Albainy-Jenei
Significant Case Studies Give You The Chance To Learn About New Partnerships and New Agreements In The Industry * BMS and Allergan * Merck and Schering-Plough * Sanofi-Aventis and Intelliject * J&J and Takeda * Eli Lilly and Kowa Pharmaceuticals * Eli Lilly and Incyte Corporation The Perfect Pitch: Biotech Investment Challenge In this groundbreaking session, Biotech companies will have the chance to present your new research and new therapies (either in early stages or mid-late… [read post]
26 Jul 2010, 11:36 am by Kevin M. Doherty, Esq.
This mirrors a similar decision we discussed in April of 2009 against Schering Corporation. [read post]